ESR1 and breast carcinoma: Interaction of YAP1 and ESR1 in nuclei is a unique feature of HR+HER2− breast cancer, and thus YAP1 could serve as a prognostic marker as well as a therapeutic target in patients with HR+HER2− breast cancer.